25_EDEN_Logo_TaglineLockup-Reversed
Contact Us

Fast-Track
Approvals

Regulatory De-Risking

  • No surprises strategy – early NRC engagement, continuous feedback, and transparent process.
  • Built on USG-funded technology – de-risks deployment.
  • Exclusive Sandia National Laboratories reactor license.
  • DOE-validated reactor design reduces complexity and risk vs. power-reactor models.
  • 5+ years of active collaboration with U.S. NRC through pre-licensing meetings.
  • Pre-application readiness review completed to accelerate Construction Permit Application.
  • Sargent & Lundy as long-term AE partner (80+ years of NRC experience).
  • Submittal for NRC license to construct by December 2025.
  • Canadian alignment: CNSC + NRC memorandum of cooperation, partnership with Cross River Infrastructure Partners.
  • Goal: NM facility licensed for construction by 1H 2027.

Eden Milestones

1989

U.S. loses sole domestic supplier of Mo-99. In response, DOE launches Medical Isotope Production Program.

1993

DOE designates Sandia and Los Alamos National Laboratories as the U.S. backup supply facilities. This work later forms technical foundation for Eden’s technology.

1996
Sandia National Laboratories successfully produces Mo-99 in current Eden reactor design.
1998

DOE program halted.

2012

Congress passes American Medical Isotopes Act.

2013

Eden is incorporated with the State of New Mexico.

2015
Eden secures exclusive license to the “All-Target Core” nuclear reactor design from Sandia National Laboratories.
2017

U.S. patent issued for All-Target Core design.

2019

Eden receives $20 million Series A investment from Abo-Empire (Abo Rad LLC). 

2020

The Eden/Sandia partnership receives the FLC National Award for Excellence in Technology Transfer.

2020-2024

Eden is awarded multiple NNSA technology work packages, totaling over $6 million dollars in value.

2023-2024

Eden hires Sargent & Lundy as its Architect-Engineer to lead the reactor and facility design, initiates regular pre-application meetings with the Nuclear Regulatory Commission (NRC), successfully completes NRC readiness reviews, and progresses reactor and facility design to a level suitable for NRC docketing and review.

2025

PSAR readiness assessment by NRC. MOU Signed with Cross River Infrastructure Partners.

2025

Submit construction permit application to NRC.

Timeline to Market​

2025–2026

NRC pre-licensing process + Canada site selection.

2026–2027

NRC licensing; U.S. construction permit secured → Series C preparation.

2027–2029

Facility construction, equipment fabrication, QA and staffing.

2029–2030

Commissioning and regulatory verification.

2030

Initial isotope production (Mo-99 + Lu-177) and contracted revenue.

2032+

Full-scale operations → expansion to new isotopes and export markets.